Milnacipran new antidepressor clinical tolerability;Tolerance clinique d'un nouvel antidepresseur, le milnacipran

Encephale

Volumn 25, Issue 3, 1999, Pages 252-258

  Regina, W ^a   Vandel, P ^a   Vandel, S ^b   Sechter, D ^a   Bizouard, P ^a  

^a HÔPITAL SAINT JACQUES   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Clinical tolerability; Comedication; Inpatients; Milnacipran

Indexed keywords

ANTIDEPRESSANT AGENT; ATENOLOL; CAFEDRINE; DEXTROPROPOXYPHENE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; FUROSEMIDE; HEPTAMINOL; LEVOMEPROMAZINE; LEVOTHYROXINE; LOSARTAN POTASSIUM; METOPIMAZINE; MILNACIPRAN; NICARDIPINE; NORADRENALIN UPTAKE INHIBITOR; OMEPRAZOLE; PHENOTHIAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; THEODRENALINE; VALPROMIDE; CYCLOPROPANE DERIVATIVE; DRUG DERIVATIVE; NOREPHENDRINETHEOPHYLLINE; PHENYLPROPANOLAMINE; THEOPHYLLINE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; DYSURIA; FEMALE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPOTENSION; MALE; NAUSEA; POLLAKISURIA; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; HOSPITALIZATION; MAJOR DEPRESSION; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; AGED; CARDIOVASCULAR DISEASES; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPTAMINOL; HOSPITALIZATION; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; PHENYLPROPANOLAMINE; SEROTONIN UPTAKE INHIBITORS; THEOPHYLLINE; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0032807594     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. ABERNETHY DR, GREENBLATT DJ, MORSE DS. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. Br J Clin Pharmacol 1985 ; 19 : 51-7.
2. ABERNETHY DR, GREENBLATT DJ, STEEL K. Impairement of hepatic drug oxidation by propoxyphene. Ann Intern Med 1982 ; 97 : 223-4.
3. BAKER GB, FANG J, SHINHA S et al. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev 1998 ; 22 (2) : 325-33.
4. BERTSCHY G, VANDEL S, VANDEL B et al. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 1991 ; 40 : 119-20.
5. BRILEY M, PROST JF, MORET C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996 ; 11 : 10-4.
6. GLASSMAN AH, WALSH BT, ROOSE SP. Factors related to orthostatic hypotension associated with tricyclic antidepressants. J Clin Psychiatry 1982 ; 43 : 35-8.
7. KASPER S, PLETAN Y, SOLLES A et al. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression : a summary of clinical trial results, Int Clin Psychopharmacol 1996 ; 11 : 35-9.
8. LECRUBIER Y, PLETAN Y, SOLLES A et al. Clinical efficacy of milnacipran : placebo-controled trials, Int Clin Psychopharmacol 1996 ; 11 : 29-33.
9. LOPEZ-IBOR J, GUELFI JD, PLETAN Y et al. Milnacipran and selective serotonin reuptake inhibitors in major depression, Int Clin Psychopharmacol 1996 ; 11 : 41-6.
10. MONTGOMERY SA, PROST JF, SOLES A et al. Efficacy and tolerability of milnacipran : an overview, Int Clin Psychopharmacol 1996 ; 11 : 47-51.
11. NEMEROFF CB, DE VANE CL, POLLOCK BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996 ; 153 : 311-20.
12. PUOZZO C, LEONARD BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996 ; 11 : 15-27.
13. SWETT CJR, COLE JO, HARTZ SC. Hypotension due to chlorpromazine : relation to cigarette smoking, blood pressure, and dosage. Arch Gen Psychatry 1997 ; 34 : 661-3.
14. VANDEL S, BERTSCHY G, BAUMANN P et al. Fluvoxamine and fluoxetine : interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995 ; 31 : 347-53.
15. VANDEL S, BERTSCHY G, BOUQUET S et al. Fluoxetine and nor-fluoxetine plasma levels after discontinuation in man. Therapie 1994 ; 49 : 141-2.
16. WONG SL, CAVANAUGH J, SHI H. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996 ; 60 : 48-53.
17. ZACARRA G, MESSORI A, MORONI F. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1988 ; 15 : 367-89.